Zydus Cadila has received the final approval from the USFDA to market Risedronate Sodium Delayed-Release Tablets (US RLD — ATELVIA® delayed-release tablets), 35 mg. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
Risedronate is a medicine of bisphosphonate group that alters bone formation and breakdown in the body. This can slow bone loss and may help prevent bone fractures. This medicine is used to treat osteoporosis in women, caused by menopause.
The group now has 218 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.408.3 as compared to the previous close of Rs. 408.65. The total number of shares traded during the day was 233794 in over 3129 trades.
The stock hit an intraday high of Rs. 412.95 and intraday low of 400. The net turnover during the day was Rs. 95318217.